Adipotide: research

A fat-blood-vessel targeting peptide with monkey weight-loss data and kidney toxicity.

Also called: FTPP, FTTP, Prohibitin-TP01, Prohibitin-targeting peptide 1, CKGGRAKDC-GG-D(KLAKLAK)2.

Fat-loss peptides · Prohibitin-targeted proapoptotic peptidomimetic.

One registered phase 1 trial enrolled four men; no results posted. Seven animal study entries cover five papers, with three separate monkey cohorts.

Studies

Adipotide dosage

Typical reported dose: 1 mg once a day in 30-day cycles

  • 1 mg daily, 30-day cycles: 1 mg once daily on days 1–30 once daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)
  • 2.5 mg daily, 25 days: 2.5 mg daily on days 1–25 once daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)
  • 1 to 3 mg during a 28-day cycle: Days 1–1 or 1–2: 1 mg daily; then 3 mg daily, then 3 mg once daily through day 28 once daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)
  • 500 mcg morning and night: 500 mcg each morning and night on days 1–30 twice daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Adipotide side effects and risks

Reported side effects

  • Kidney tubular injury and higher creatinine: Human rate unknown. In lean monkeys at 0.43 mg/kg, creatinine rose sporadically in 2/5., serious. Stop use and seek prompt kidney assessment; symptoms may be absent. (source)
  • Potassium and phosphate loss: Dose related changes in monkeys; no human event rates., serious. Check electrolytes and kidney function; do not self-correct with large potassium doses. (source)
  • Sugar or protein leaking into urine: Mild–marked urine glucose and mild–moderate protein in monkeys; human rate unknown., serious. Urine testing can reveal injury even when you feel well. (source)
  • More urination and dehydration: Observed in monkeys; dehydration was noted at the highest doses., moderate. Prompt assessment for thirst, dizziness or changing urine output. (source)
  • Burning, itching, lumps or welts at injection sites: Several online accounts; no denominator or verified human rate., moderate. Persistent or worsening swelling needs clinical review. (source)
  • Flushing, fatigue or headache: One online log; no clinical incidence estimate., mild. New or persistent symptoms warrant review rather than dose escalation. (source)
  • Reduced appetite: Observed in rodents and monkeys and reported online; human rate unknown., moderate. Track intake and hydration; unexplained rapid weight loss needs assessment. (source)

Stop and get help if

  • Much less urine, swollen legs, vomiting, severe thirst or new breathlessness: Stop exposure and seek urgent medical assessment for possible kidney injury.
  • New confusion, severe drowsiness, collapse or trouble breathing: Seek emergency care now; do not wait for a routine blood test.
  • Swollen tongue or throat, wheezing or fainting after an injection: Call emergency services now for possible severe allergy.
  • A new rise in creatinine or new glucose/protein in urine, even without pain: Stop exposure and arrange prompt clinician review; painless injury is possible.

Who should avoid it

  • pregnant: Pregnancy safety is unknown. No women were enrolled in the only human trial.
  • breastfeeding: Milk transfer and infant safety are unknown; no breastfeeding data were found.
  • tryingToConceive: Fertility and embryo safety are unknown. The human trial required contraception.
  • under18: The trial excluded anyone under 18; no pediatric safety data were found.
  • kidneyDisease: Kidney tubular injury occurred in monkeys. The human trial required adequate kidney function.
  • other: Dehydration can worsen kidney injury; adipotide caused urine and electrolyte losses in monkeys.
  • other: The trial excluded uncorrected blockage affecting both kidneys or a solitary kidney.
  • uncontrolledBloodPressure: The trial excluded chronic uncontrolled blood pressure because of possible existing kidney damage.
  • heartCondition: Recent heart attack, unstable angina and severe heart failure were excluded from the human trial.
  • liverDisease: The trial excluded chronic liver disease with scarring or impaired liver function.
  • diabetes: Uncontrolled diabetes was excluded. Animal glucose changes make medication review important.
  • eatingDisorderHistory: Food intake fell in animal studies. With no human safety data, appetite and weight effects are a concern.
  • activeCancer: The only human trial involved prostate cancer and has no results. Any use needs oncology review.
  • surgeryPlanned: Kidney injury risk warrants review before surgery, fasting or exposure to other kidney-stressing drugs.
  • testedAthlete: S0 of the 2026 WADA List covers unapproved substances at all times; this applies to adipotide.

Interactions

  • NSAID pain medicines: The trial barred ongoing NSAIDs and required avoidance through 30 days after dosing. Aspirin ≤81 mg/day was excepted; review prescribed aspirin first.
  • Strongly kidney-toxic medicines: The trial excluded IV vancomycin, aminoglycosides and other strongly kidney-toxic drugs. Added kidney harm is a concern.
  • Insulin and sulfonylureas: Potential low blood sugar if insulin sensitivity or food intake changes. This is an animal-based precaution; no human interaction study exists.
  • Diuretics and kidney-sensitive blood-pressure drugs: Fluid loss may increase kidney risk. This is a general kidney precaution, not a measured adipotide interaction; review medicines before changing them.
  • Other weight-loss peptides: Stacks are reported online, without controlled combination safety data. Animal kidney harm and reduced intake remain concerns.
  • Purported kidney-protection supplements or peptides: Forum users discuss protection, but no adipotide study establishes that these prevent kidney injury.

Product quality risks

  • No published test-buy study of online adipotide was found; its real-world purity and dose accuracy are unknown.
  • In three online semaglutide samples, purity was 7%–14% and drug content 29%–39% above label. This is indirect evidence, not adipotide testing.
  • One semaglutide sample contained 8.95 EU/mg endotoxin despite no viable microbes detected. A sterility result alone misses this risk.
  • TGA reports poorly labelled unapproved peptide vials with uncertain ingredients, manufacturing and sterility.

How Adipotide works

One part binds prohibitin on blood vessels that feed white fat. Another part damages the cell’s energy machinery and triggers cell death. This reduced fat in animals. Reduced eating also contributed; the same effect has not been shown in people.

  • Cell-surface prohibitin in white-fat blood vessels: The CKGGRAKDC targeting sequence helps deliver the attached cell-killing peptide.
  • Mitochondrial membranes: The D(KLAKLAK)2 part disrupts cell energy machinery after entering a target cell.
  • Food-intake regulation: Reduced eating explained much of the weight loss in rodent studies; the signal remains unclear.

Half-life: Human half-life is unknown; planned blood sampling produced no public results.

Gaps: No public outcomes, adverse-event rates or actual dose history for the four trial participants. The trial stop reason is investigator request; a safety cause cannot be established from the registry. No established human maximum dose: aboveStudied=false means comparison is unknown, not that community doses are within a safe limit. No label or published human trial protocol is included; the registry starting dose appears only in the study description. No clinician-published adipotide dosing protocol or systematic review of human outcomes was located. No reliable human half-life, bioavailability, fertility, pregnancy, breastfeeding or long-term safety data. Community prevalence is unknown. Retrieved daily totals span 0.333–5 mg; one recalled range was 0.5–1 mg on five days each week. One user recalled five days on/two off; the route was unstated. No verified microdosing or safe cycling method was found. A forum formula of 43–50 mcg/kg was mentioned but not taken by that poster; it is not a validated human dose. Online advice also mentions 0.01 mg/kg/day, without evidence of an actual completed regimen or a validated dose. Syringe-unit and mg/kg conflicts in one log prevent a usable mass-dose schedule. No human combination study or proven kidney-protective stack was located. No adipotide-specific stability, sterility, contamination, poison-center series or verified market-purity study was found. No adipotide-specific FDA PCAC decision or warning letter located; category-list absence does not rule out a newer nomination. EU national approvals, country-specific import/possession rules and Australian scheduling remain incompletely resolved.

Related to Adipotide

Adipotide: the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.